Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-? for the treatment of patients with advanced renal cell carcinoma

Elias, Laurence; Lew, Danika; Figlin, Robert A.; Flanigan, Robert C.; Thompson, Mark E.; Triozzi, Pierre L.; Belt, Robert J.; Wood, David P.; Rivkin, Saul E.; Crawford, E. David

doi:10.1002/1097-0142(20000801)89:3<597::aid-cncr15>3.0.co;2-e

Cited by 22 publications

(8 citation statements)

References 22 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This protocol is closely related to the schedule designed for other clinical research trials with IL-2, IFNa and 75-FU within the framework of the French Immunotherapy Group Négrier et al, 2000). These large studies showed an unexpectedly low response rate Négrier et al, 2000) like the present study, compared to more promising results obtained by others (Atzpodien et al, 1993;Hofmockel et al, 1996;Joffe et al, 1996;Ellerhorst et al, 1997;Tourani et al, 1998;Allen et al, 2000;Dutcher et al, 2000;Elias et al, 2000;van Herpen et al, 2000).…”

Section: Discussionsupporting

confidence: 66%

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial

et al. 2003

View full text Add to dashboard Cite

The association of interleukin-2 (IL-2), interferon alpha-2a (IFNa), 5-fluorouracil (5-FU) has been reported to induce response in metastatic renal cell carcinoma (MRCC). This study evaluated IL-2, IFNa and 5FU as second-line treatment after failure under immunotherapy. A total of 35 patients received IL-2, at 9 Â 10 6 IU m À2 , once or t.i.d, 5 days a week, every other week. Interferon alpha was administered at 6 MUI, TIW along with IL-2 every week. 5-Fluorouracil was given at 750 mg m À2 day À1 on days 1 -5 every 4 weeks. One cycle lasted 8 weeks. All patients were evaluable for response and toxicity. There were two objective responses (5.7%) and 14 stable diseases (40%). Survival was 14 months. In all, 17 patients experienced grade 3 toxicity. The predictive factor for progression to second-line immunotherapy was the results of first-line immunotherapy, and performance status, delay from primary tumour to metastases and response or stabilisation to chemo-immunotherapy for survival. IL-2, IFNa and 5-FU induce low objective response but stabilisation in patients with MRCC having failed with immunotherapy, and may be considered only in selected patients on performance status, stabilisation or response after first-line immunotherapy and interval from their primary tumour to metastases.

show abstract

Section: Discussionsupporting

confidence: 66%

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Fig 2 illustrates a comparison of schedules used in three combinations of 5-FU, IL-2, and IFN-α that have been reported with divergent response rates. [36][37][38] A direct, randomized comparison of high-dose inpatient IL-2 and an outpatient schedule restricted to patients who would otherwise be eligible for inpatient high-dose IL-2 has been presented (favoring the high-dose cohort, discussed later). 39 Improved tolerability would allow more patients to consider starting, as well as successfully complete, the treatment courses.…”

Section: Subcutaneous Il-2mentioning

confidence: 99%

Immunotherapy of Metastatic Renal Cell Cancer

Fishman

Seigne

2002

Cancer Control

View full text Add to dashboard Cite

“…However, the combination of low dose IL-2 with other treatment modalities, such as INF-␣ [32], 5-FU [33,34], and TIL [35], have not been more efficacious than single-agent low-dose IL-2. Collectively, these results indicate that the IL-2-based treatment regimens that are currently available are limited by toxicity profiles or lack of tumor response.…”

Section: Toward a More Specific And Less Toxic Immunotherapy Approachmentioning

confidence: 99%

The role of adjuvant immunotherapy in renal cell carcinoma

Mulders

Mulder

2002

Curr Urol Rep

View full text Add to dashboard Cite

After nephrectomy for renal cell carcinoma (RCC), a significant number of patients develop recurrent disease. In order to improve the prognosis of these patients, the role of adjuvant immunotherapy should be clarified; the appropriate selection of patients is especially crucial. For this purpose, the search for prognostic factors is important to identify at-risk patients. Known factors such as stage, grade, and microvascular invasion can be used for appropriate selection. Other molecular markers, such as cadherin-6 and G250 antigen, may become important. So far, adjuvant immunotherapy in RCC has not shown improved survival data, but the results may be hampered by inadequate recruitment and follow-up. Adequate selection of patients and the search for less toxic and more effective immunotherapy approaches are of importance. Therefore, the use of monoclonal antibody G250 or dendritic cell vaccinations, alone or together with cytokines, may be advantageous and is currently used. Today, adjuvant protocols are open for recruitment of patients to elucidate the important question as to whether this approach should be implemented in the treatment of RCC. In this article, an update is given in the field of adjuvant immunotherapy in patients with RCC.

show abstract

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-? for the treatment of patients with advanced renal cell carcinoma

Cited by 22 publications

References 22 publications

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial

Immunotherapy of Metastatic Renal Cell Cancer

The role of adjuvant immunotherapy in renal cell carcinoma

Contact Info

Product

Resources

About